** U.S.-listed shares of Israel-based drug developer PolyPid PYPD.O fell 4.7% to $2.75

** Company, which develops therapies to improve surgical outcomes, posts quarterly loss of $1.13 per share vs analysts' estimate loss of 88 cents

** Says independent monitoring board recommended to conclude late-stage study of experimental drug upon enrollment of 800 patients

** PYPD is testing the treatment to prevent surgical site infections in patients undergoing a type of abdominal cancer surgery

** Expects to report data from the late-stage in the second quarter of 2025 and plans to submit a marketing application to the FDA if the study meets the main goal

** In the last 12 months, stock has fallen 48.7%

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))